| Literature DB >> 20459780 |
Yu Gao1, Laurence Flori, Jérome Lecardonnel, Diane Esquerré, Zhi-Liang Hu, Angélique Teillaud, Gaëtan Lemonnier, Francois Lefèvre, Isabelle P Oswald, Claire Rogel-Gaillard.
Abstract
BACKGROUND: Designing sustainable animal production systems that better balance productivity and resistance to disease is a major concern. In order to address questions related to immunity and resistance to disease in pig, it is necessary to increase knowledge on its immune system and to produce efficient tools dedicated to this species.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20459780 PMCID: PMC2881026 DOI: 10.1186/1471-2164-11-292
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Construction of SLA-RI/NRSP8-13K chip
| Sets | Probes | Number of probes | Number of genes |
|---|---|---|---|
| gene or pseudogenes | 804 | ||
| non-coding RNA | 12 | ||
| Porcine sequence | 2832 | ||
| Human sequence | 125 | ||
| 92 | |||
| 40 | |||
| 1998 | |||
1 The total gene number is 10010 because 1635 genes are found in both gene sets
Figure 1Venn diagram representing the number of probes that were found differentially expressed after LPS or PMA/ionomycin stimulation compared to mock-stimulation. The number of probes identified from the SLA-RI subset is indicated within brackets. The number of genes sharing the same GO is indicated in squares connected to the different parts of the diagram by arrows. GO annotations that were found specific to LPS or PMA/ionomycin stimulation are indicated in italic letters.
Number of probes differentially expressed by PBMCs stimulated with LPS or PMA/ionomycin
| Probe set | Regulation | LPS | PMA/ionomycin |
|---|---|---|---|
| SLA-RI | Up | 98 | 377 |
| Down | 64 | 492 | |
| Sub-total | 162 | 869 | |
| NRSP8-13K | Up | 165 | 1999 |
| Down | 76 | 1161 | |
| Sub-total | 241 | 3160 | |
| Total | 403 | 4029 | |
Top ten genes found differentially up- or down-regulated after LPS or PMA/ionomycin stimulation
| LPS stimulation | PMA/ionomycin stimulation | |||||
|---|---|---|---|---|---|---|
| Up-regulation | SAA1 | C4 | 26.84 | IL2 | No3 | 9.96 |
| IL8 | C3 | 23.96 | HSP90AB1 | C6 | 8.49 | |
| CCL2 | C4 | 13.36 | NPM1 | C6 | 8.21 | |
| S100A9 | C3 | 13.33 | CD69 | No3 | 6.87 | |
| CXCL5 | C4 | 12.42 | TNFRSF9 | No3 | 6.62 | |
| S100A12 | No3 | 10.92 | NPM3 | C6 | 6.61 | |
| CXCL3 | No3 | 9.55 | HSPD1 | C6 | 6.51 | |
| CXCL2 | No3 | 7.96 | GAPDH | C6 | 6.20 | |
| CCL8 | No3 | 7.36 | RPS2 | C6 | 5.31 | |
| SOD2 | C6 | 5.85 | RAN | C6 | 5.31 | |
| Down-regulation | LYZ1 | C1 | -8.59 | THBS1 | C2 | -65.98 |
| FN11 | C1 | -7.57 | FOLR11 | C1 | -19.74 | |
| SLA-DRB1 | C8 | -3.23 | LYZ1 | C1 | -14.76 | |
| FOLR11 | C1 | -3.21 | FN11 | C1 | -12.26 | |
| CST31 | C8 | -2.80 | CSF1R | C8 | -8.15 | |
| SLA-DQB1 | C8 | -2.74 | TGFBI | C8 | -6.78 | |
| SLA-DOB | C8 | -2.69 | CST31 | C8 | -6.51 | |
| CST21 | C8 | -2.67 | CST21 | C8 | -5.80 | |
| SLA-DRA | C8 | -2.65 | CD163 | No3 | -5.59 | |
| SLA-DQA1 | C8 | -2.40 | CTSZ | C8 | -5.58 | |
1 Genes that are commonly down-regulated after LPS or PMA/ionomycin stimulation
2 The clusters refer to the hierarchical clustering reported in Figure 2 and Additional file 4
3 "No" means that the genes were found differentially expressed in only one stimulation condition and were not included in the hierarchical clustering.
Figure 2Hierarchical clustering of the 316 probes found differentially expressed after LPS and PMA/ionomycin stimulations (Fisher p-value). The eight clusters C1 to C8 are partially represented. The whole clusters are provided in Additional file 4: SLA_RI_Figure_S4.png.
Figure 3Numbers of molecules in biological function categories related to the catalogs Diseases and Disorders (A), Molecular and Cellular Function (B) and Physiological System Development and Function (C) by IPA system.
LPS and PMA/ionomycin stimulation: top biological functions from the catalogs Diseases and Disorders1, Molecular and Cellular Functions2 and Physiological System Development and Function3 identified by IPA and number of focus genes
| Stimulation | Top biological functions | Fisher p-value | |
|---|---|---|---|
| LPS | Cellular Growth and Proliferation2 | 126/2404 | 2.25E-18 - 7.17E-07 |
| Cell Death2 | 114/2259 | 2.00E-27 - 9.59E-07 | |
| Immunological Disease1 | 113/1730 | 3.40E-46 - 9.59E-07 | |
| Immune Response3 | 113/475 | 6.00E-23 - 9.56E-07 | |
| Inflammatory Disease1 | 108/401 | 2.58E-45 - 1.06E-06 | |
| Hematological System Development and Function3 | 101/1446 | 6.70E-28 - 8.53E-07 | |
| Cell-To-Cell Signaling and Interaction2 | 99/1465 | 2.44E-24 - 4.29E-07 | |
| Cellular Movement2 | 92/1364 | 6.70E-28 - 8.33E-07 | |
| Immune and Lymphatic System Development and Function3 | 92/430 | 3.43E-19 - 8.03E-07 | |
| Skeletal and Muscular Disorders1 | 83/2024 | 2.52E-39 - -2.26E-07 | |
| Cellular Development2 | 82/1899 | 1.66E-15 - 1.08E-06 | |
| Connective Tissue Disorders1 | 80/145 | 2.52E-39 - -2.26E-07 | |
| Tissue Morphology3 | 73/943 | 4.02E-20 - 8.53E-07 | |
| Tissue Development3 | 68/1374 | 6.06E-18 - 5.30E-07 | |
| Infectious Disease1 | 63/1087 | 1.60E-32 - 1.08E-06 | |
| PMA/ionomycin | Cancer1 | 913/2395 | 5.41E-25 - 5.07E-08 |
| Cellular Growth and Proliferation2 | 826/2404 | 3.15E-48 - 1.18E-08 | |
| Cell Death2 | 725/2259 | 1.10E-32 - 5.07E-08 | |
| Cellular Development2 | 491/1899 | 3.61E-32 - 4.90E-08 | |
| Hematological System Development and Function3 | 481/1446 | 1.34E-35 - 4.73E-08 | |
| Immune Response3 | 451/475 | 1.34E-35 - 4.73E-08 | |
| Immunological Disease1 | 433/1730 | 1.83E-52 - 3.92E-08 | |
| Immune and Lymphatic System Development and Function3 | 415/430 | 1.34E-35 - 2.91E-08 | |
| Inflammatory Disease1 | 377/401 | 5.57E-36 - 4.26E-09 | |
| Cell Cycle2 | 360/1017 | 4.35E-26 - 4.78E-08 | |
| Skeletal and Muscular Disorders1 | 327/2024 | 5.57E-36 - 3.41E-08 | |
| Tissue Morphology3 | 313/943 | 1.10E-32 - 2.30E-08 | |
| Connective Tissue Disorders1 | 294/145 | 5.57E-36 - 5.29E-09 | |
| Organismal Survival3 | 290/971 | 1.10E-15 - 2.41E-08 | |
| Protein Synthesis2 | 242/534 | 1.30E-29 - 6.66E-09 | |
1 Diseases and Disorders
2 Molecular and Cellular Functions
3 Physiological System Development and Function
4 Number of genes found differentially expressed after LPS or PMA/ionomycin stimulation divided by the total number of genes represented on the array for the biological functions
Figure 4LPS-related gene networks identified by IPA. A: network 1, B: network 2, C: network 3. The network numbers refer to the numbers reported in Additional file 5: SLA_RI_Table_S5.xls.
List of KEGG biological pathways associated with the genes differentially expressed after LPS or PMA/ionomycin stimulation
| Stimulation | KEGG pathway | Symbol | Fisher p value | |
|---|---|---|---|---|
| LPS | Cytokine-cytokine receptor interaction | CCRI | 29/233 | 1.00E-08 |
| Antigen processing and presentation | AP_&_P | 15/57 | 3.10E-07 | |
| Toll-like receptor signaling pathway | TLR | 15/89 | 1.88E-06 | |
| Cell adhesion molecules | CAMs | 13/120 | 6.85E-04 | |
| Hematopoietic cell lineage | HCL | 13/83 | 9.03E-06 | |
| Apoptosis | Apop | 11/76 | 1.41E-04 | |
| Type I diabetes mellitus | T1D | 10/31 | 1.88E-06 | |
| B cell receptor signaling pathway | B_cell | 8/67 | 1.60E-03 | |
| Adipocytokine signaling pathway | Adip | 7/58 | 1.25E-02 | |
| Small cell lung cancer | SCLC | 7/126 | 3.21E-02 | |
| T cell receptor signaling pathway | T_cell | 7/99 | 4.37E-02 | |
| Complement and coagulation cascades | CCC | 6/69 | 3.30E-02 | |
| Epithelial cell signaling in Helicobacter pylori infection | ECs | 6/59 | 3.10E-02 | |
| Acute myeloid leukemia | AML | 5/53 | 4.84E-02 | |
| Bladder cancer | BC | 5/39 | 1.49E-02 | |
| Alzheimer's disease | AD | 4/122 | 1.55E-02 | |
| PMA/ionomycin | Cytokine-cytokine receptor interaction | CCRI | 74/233 | 4.86E-02 |
| Oxidative phosphorylation | OP | 63/96 | 0.00E+00 | |
| Ribosome | Ribosome | 55/78 | 0.00E+00 | |
| Cell adhesion molecules | CAMs | 47/120 | 1.98E-03 | |
| Jak-STAT signaling pathway | Jak-STAT | 46/129 | 4.96E-02 | |
| Natural killer cell mediated cytotoxicity | NK | 44/102 | 9.13E-03 | |
| Cell cycle | Cell_cycle | 41/93 | 3.11E-03 | |
| Toll-like receptor signaling pathway | TLR | 40/89 | 4.14E-04 | |
| Leukocyte transendothelial migration | LTEM | 39/108 | 1.36E-02 | |
| Hematopoietic cell lineage | HCL | 38/83 | 5.22E-05 | |
| T cell receptor signaling pathway | T_cell | 38/99 | 2.16E-04 | |
| Antigen processing and presentation | AP_&_P | 37/57 | 7.05E-05 | |
| Chronic myeloid leukemia | CML | 30/64 | 1.88E-03 | |
| Pyrimidine metabolism | Pyrimidine | 30/68 | 2.07E-02 | |
| TGF-beta signaling pathway | TGF-beta | 30/69 | 2.82E-02 | |
| B cell receptor signaling pathway | B_cell | 28/67 | 3.85E-04 | |
| Adherens junction | AJ | 25/68 | 4.27E-02 | |
| Fc epsilon RI signaling pathway | FeRI | 25/66 | 4.27E-02 | |
| Adipocytokine signaling pathway | Adip | 24/584 | 4.65E-02 | |
| Renal cell carcinoma | RCC | 24/62 | 2.84E-02 | |
| Acute myeloid leukemia | AML | 23/53 | 4.47E-03 | |
| Glycolysis/Gluconeogenesis | Glycolysis | 23/40 | 1.76E-02 | |
| Pathogenic Escherichia coli infection - EHEC | EHEC | 21/42 | 8.24E-03 | |
| Pathogenic Escherichia coli infection - EPEC | EPEC | 21/42 | 8.24E-03 | |
| Proteasome | Proteasome | 21/43 | 0.00E+00 | |
| Type I diabetes mellitus | T1D | 18/31 | 9.62E-03 | |
| Pyruvate metabolism | Pyruvate | 17/31 | 1.32E-02 | |
| Neurodegenerative Disorders | ND | 16/32 | 1.38E-02 | |
| Aminoacyl-tRNA biosynthesis | AA-tRNA | 15/28 | 2.47E-02 | |
| Citrate cycle (TCA cycle) | TCA_cycle | 13/27 | 1.12E-02 | |
| Propanoate metabolism | Propanoate | 13/23 | 4.57E-02 | |
| Thyroid cancer | TC | 12/26 | 2.91E-02 | |
| Prion disease | PD | 8/34 | 7.98E-03 | |
| Glycosphingolipid biosynthesis - globoseries | Globoseries | 7/43 | 3.12E-02 | |
| Fatty acid elongation in mitochondria | FAE | 6/10 | 1.62E-02 | |
| Phenylalanine, tyrosine and tryptophan biosynthesis | FYW | 5/10 | 4.18E-02 | |
| Biotin metabolism | Biotin | 3/7 | 4.56E-02 | |
1 Number of genes found differentially expressed after LPS or PMA/ionomycin stimulation divided by the total number of genes represented on the array for the KEGG pathways
Figure 5Interactions of KEGG biological pathways identified with genes found differentially expressed after LPS (A) or PMA/ionomycin stimulation (B). The pathway symbols are indicated in Table 5. The circle size allocated to the pathways is proportional to the number of genes in each pathway.
Figure 6PMA/ionomycin-related gene networks identified by IPA. A: network 1, B: network 53, C: network 57 in which THBS1 and CD47 were assembled by connection between CD69 and THBS1 in network 94 that was not presented here. The network numbers refer to the numbers reported in Additional file 7: SLA_RI_Table_S7.xls.
List of differentially expressed genes in MHC class I and class II presentation pathways after stimulation by LPS or PMA/ionomycin
| Stimulation | Pathway | Gene symbol (Pig) | Fold Change |
|---|---|---|---|
| LPS | MHC I pathway | HSP90AB1 | 1.44 |
| HSPA5 | 1.41 | ||
| PSMB8 | 1.27 | ||
| PSME2 | 1.33 | ||
| MHC II pathway | CD74 | -2.01 | |
| CTSB | -1.38 | ||
| CTSL1 | 2.80 | ||
| CTSS | -1.61 | ||
| LGMN | -1.81 | ||
| SLA-DMA | -1.82 | ||
| SLA-DMB | -2.12 | ||
| SLA-DOB | -2.69 | ||
| SLA-DQA | -2.40 | ||
| SLA-DQB | -2.34 | ||
| SLA-DRA | -2.50 | ||
| SLA-DRB1 | -2.28 | ||
| SLA-DRB3 | -1.68 | ||
| PMA/ionomycin | MHC I pathway | CALR | 1.84 |
| CANX | 1.64 | ||
| HSP90AA1 | 2.06 | ||
| HSP90AB1 | 7.72 | ||
| HSP90B1 | 1.87 | ||
| HSPA1A | 1.52 | ||
| HSPA1B | -1.27 | ||
| HSPA1L | -1.33 | ||
| HSPA4 | 1.55 | ||
| HSPA5 | 1.84 | ||
| HSPA6 | 3.46 | ||
| HSPA8 | 4.16 | ||
| HSPA9 | 2.95 | ||
| HSPBP1 | 1.66 | ||
| IFNA5 | -1.48 | ||
| LTA | 2.18 | ||
| PDIA3 | 1.79 | ||
| PSMB5 | 2.68 | ||
| PSMB6 | 2.55 | ||
| PSMB8 | 2.10 | ||
| PSMB9 | 2.43 | ||
| PSME1 | 2.16 | ||
| PSME2 | 2.56 | ||
| SLA-3 | -1.29 | ||
| SLA-4 | -1.26 | ||
| SLA-6 | -2.01 | ||
| SLA-7 | -1.29 | ||
| SLA-11 | -1.95 | ||
| TAP1 | 1.85 | ||
| TAP2 | 1.41 | ||
| TNF-a | 2.83 | ||
| TRAP1 | 1.53 | ||
| MHC II pathway | CD74 | -2.40 | |
| CTSB | -2.24 | ||
| CTSS | -3.01 | ||
| LGMN | -3.71 | ||
| SLA-DMA | -2.06 | ||
| SLA-DMB | -2.31 | ||
| SLA-DOA | -1.38 | ||
| SLA-DOB | -2.50 | ||
| SLA-DQA | -3.14 | ||
| SLA-DQB | -2.62 | ||
| SLA-DRA | -2.83 | ||
| SLA-DRB1 | -3.12 | ||
| SLA-DRB3 | -2.05 | ||
| SLA-DRB5 | -1.35 | ||
Primer sequences for qRT-PCR validation
| Gene name (Symbol) | Forward | Reverse | Amplicon size (bp) | Accession number |
|---|---|---|---|---|
| B2M1 | TGGTCTTTCTACCTTCTGGTCC | TGTGATGCCGGTTAGTGGTCTC | 134 | NM_004048 |
| CD69 | TCCTATCCCATGTGCTGTGGT | GCACATATTGGCCTGGACAGT | 104 | NM_214091 |
| CST2 | TCTTGGAAGTGGAGATTGGCC | CACAGCGTTTTCTTCTGCAGG | 103 | BG609449 |
| IL1A | GTGTGGTGATGGCAGCAGC | GGTCGTCATCGGTGATGAACT | 81 | NM_214029 |
| PSMB9 | GCGCTTCACCACAAATGCTA | TCCACACCAGCAGCTGTAATG | 96 | NM_001037961 |
| PSMB8 | TACCTGCTTGGCACCATGTCT | AGTACAACCTGCACTCCTTGGC | 82 | NM_213935 |
| LYZ | TCTTGCGCTTCTCCTCCTTTC | AAACATACCCAGTTCGCCAGG | 129 | NM_214392 |
| PPIA | GTCTCCTTCGAGCTGTTTGCA | CCAAATCCTTTCTCCCCAGTG | 83 | NM_214353 |
| SLAIa | CATCATTGTTGGCCTGGTTC | CCTTTTTCACCTGAGCGC | 90 | NM_001097431(SLA-1) |
| SLA-DQB | AGGAGATGTCTACACCTGCCG | ATTCAGACTGTGCCCGCC | 80 | NM_001113694 |
| SLA-DRA | ATGGGCTATCGTAGAGAATCACG | CAAACATAAACTCGCCAGATTTG | 80 | NM_001113706 |
| SLA-DRB1 | CACAGTGGAATGGAGGGCAC | AGCAGACCCAGGACGAAGC | 81 | NM_001113695 |
| TAP1 | CCAGTATCTCAGGGATGTTGCTG | CGCTGCTTATAGCCCCACC | 81 | NM_001044581 |
| TAP2 | TGTTGGGTGAGACACTAATCCCTTA | CAAAGGCATCAGGGTCAAAATC | 81 | DQ227991 |
| TNFRSF9 | TCCAGGTCACACTTCCCATGT | GAACAACAGAGAAACGGAGCG | 101 | BE233113 |
1 Reference gene for qRT-PCR
Figure 7Comparison between microarray-based and qRT-PCR-based results by Pearson correlation scattered plots.
Comparison of gene expression fold change between stimulated and non stimulated PBMCs at the protein (ELISA tests) and RNA levels (microarray)
| LPS stimulation fold change1 | PMA/ionomycin stimulation fold change1 | |||
|---|---|---|---|---|
| IL8 | 23.95 | 105.79 | 3.12 | 36.73 |
| IL12 | 1.03NS | 7.66 | 1.43 | 7691.24 |
| TNFA | 1.23NS | 7.48 | 2.83 | 1126.79 |
| IL1B | 5.00 | 144.81 | 1.04NS | 136.62 |
1NS: not significant at p value < 0.05.